A warm welcome and thank you to Arrotex Pharmaceuticals for joining us as a sponsor of TOGA's 2026 Lung Cancer Preceptorship. Through expert-led sessions, case discussions and opportunities to connect with colleagues, the Preceptorship supports the professional development of emerging clinicians

🚨 Applications close today! Today is the final opportunity to submit your application for TOGA's Inspirational Research Grant. If you have an early-stage research project with the potential to advance thoracic oncology, make sure your application is submitted before the deadline.

🫁 Two major international conferences. One webinar bringing together the key thoracic cancer updates. Join TOGA for our International Conference Highlights webinar, where expert speakers will unpack significant findings from WCLC and ASTRO 2026 and explore their potential impact on local

⏰ Last chance to apply! Applications for TOGA's Inspirational Research Grant close soon. If you have an innovative research idea in thoracic oncology, now is the time to submit your application and take the next step towards turning your vision into impact. Grant details: 💰 Amount: $50,000

Recognising rare mutations starts at diagnosis. 🎧 Listen to the full episode for more insights into testing, diagnosis and treatment. This podcast is sponsored by Bristol Myers Squibb. Listen on Apple > buff.ly/TP6kW90 Spotify > buff.ly/vL41W9r Show notes > buff.ly/Iet71To

If you learn nothing more, learn this... Professor Sanjay Popat reviews the management of atypical EGFR mutations in NSCLC, arguing that the broad label “EGFR-positive” is clinically unhelpful because different EGFR mutations have distinct biology, drug sensitivity and treatment implications.

🚨 Applications closing soon! The ALK+ NSCLC Inspirational Research Grant, proudly supported by TOGA and ALK Positive Australia, provides vital funding to support research that can improve understanding, treatment and care for Australians living with ALK+ NSCLC Could your research help shape the

We’re pleased to welcome Johnson & Johnson as a sponsor of our International Conference Highlights – WCLC & ASTRO 2026 webinar. With their support, we’re able to bring our community together to hear expert insights into the latest thoracic cancer research and its potential impact on local practice.

A warm welcome and thank you to Medison for supporting TOGA's 2026 Lung Cancer Preceptorship. Your partnership helps make high-quality education and collaboration possible for emerging clinicians with an interest in thoracic oncology. We're grateful to have you on board.

📢 Last day to submit! If you’re planning to share your research concept for this round, make sure it’s in today. And if you miss the cut-off, don’t panic. The Scientific Committee continually reviews new concepts, so you’ll have more opportunities in 2027. Keep an eye out for

The treatment landscape for ROS1-positive NSCLC has expanded significantly. In the latest episode, the panel discusses the growing number of treatment options available and what this means for navigating patient care. Listen on Apple > buff.ly/TP6kW90 Spotify > buff.ly/vL41W9r

🚨 Applications closing soon! Have you submitted your application for TOGA's Inspirational Research Grant? We're looking for innovative research ideas that involve consumer voices and have the potential to make a meaningful difference in thoracic oncology. Grant details: 💰 Amount: $50,000

🫁 What were the key thoracic cancer takeaways from WCLC 2026? Join us for our webinar exploring the most important research and clinical updates from the 2026 IASLC World Conference on Lung Cancer (WCLC). Our expert speakers will unpack the findings that matter most in thoracic oncology and

A/Prof Malinda Itchins provides an update on ADOPT-Lung at the TOGA ASM 2026. This clinical trial is designed to determine if early-stage NSCLC patients who receive chemotherapy and immunotherapy prior to surgery have longer disease-free survival if they are also treated with immunotherapy after

ADOPT-Lung Recruitment Update | A/Prof Malinda Itchins | TOGA ASM 2026

A/Prof Malinda Itchins provides an update on ADOPT-Lung at the TOGA ASM. This clinical trial is designed to determine if early-stage NSCLC patients who receive chemotherapy and immunotherapy prior…

youtu.be

What role does CNS activity play in treating ROS1-positive NSCLC? In TOGA’s Conversations in Lung Cancer Research, the panel discusses the evolving intracranial activity of therapies for ROS1-positive lung cancer and what this may mean for treatment decisions. Listen to the full episode for

New research is providing valuable insights into surgical approaches for people with early-stage lung cancer. In our latest blog, we explore the findings and what they could mean for lung cancer treatment and patient care. Read the full blog > thoraciconcology.org.au/news/treatme...

Lung Cancer Surgery: Do You Need Your Whole Lung Lobe Removed? - TOGA - Thoracic Oncology Group Australasia

New evidence is changing the way surgeons approach early-stage lung cancer, with lung-sparing surgery becoming an option for carefully selected patients.

thoraciconcology.org.au

Today, on World Radiotherapy Awareness Day, we recognise the vital role radiotherapy plays in cancer care. For many people diagnosed with thoracic cancer, radiotherapy is an important part of treatment – helping to treat cancer, manage symptoms and improve quality of life. This year's theme,

What does My Brilliant Career and being a Lung Cancer Nurse have in common? Mary Duffy AM gives a presentation on the need for lung cancer survivorship clinics and how she was able to develop a comprehensive patient-centred survivorship care through a precinct-wide nurse-led survivorship clinic.

Don't miss your opportunity to bring your research vision to life. Applications for TOGA's Inspirational Research Grant is now open, providing support to promising early-stage research in thoracic oncology. Grant details: 💰 Amount: $50,000 📆 Duration: Two years

A sincere thank you to Johnson & Johnson for supporting TOGA's 2026 Lung Cancer Preceptorship. Your contribution helps bring together emerging clinicians and experienced faculty to share knowledge, explore the latest evidence and strengthen the future of thoracic oncology.

🎧 Out now: A new episode of TOGA's Conversations in Lung Cancer Research. Host A/Prof Steven Kao is joined by A/Prof Venessa Chin and Dr Ben Kong to explore the clinical features of ROS1-positive non-small cell lung cancer and the evolving diagnostic and treatment landscape in Australia.

🎙️ New episode dropping tomorrow In the next episode of TOGA's Conversations in Lung Cancer Research, we take a closer look at ROS1-positive non-small cell lung cancer. Available tomorrow wherever you get your podcasts. This podcast is sponsored by Bristol Myers Squibb.

📣 Registrations are now open! Join us for Thoracic Cancer Highlights from WCLC 2026, where our expert speakers will unpack the most significant findings from the 2026 IASLC WCLC. Hear what the latest research could mean for thoracic cancer care and how these developments may impact local clinical

⏰ Last chance to express your interest! Expressions of interest for TOGA’s 2026 Lung Cancer Preceptorship close tomorrow. If you’re an early-career clinician with an interest in thoracic oncology, don’t miss the opportunity to take part in two days of expert-led education, interactive case

Step outside your comfort zone. Prof Zarnie Lwin OAM shares why leaving your home institution and experiencing a different environment can be such an important part of professional growth. In this episode of TOGA's Conversations in Lung Cancer Research, she reflects on the impact of her

Prof Zarnie Lwin OAM shares some advice for junior faculty and trainees beginning their careers in lung cancer research and clinical care. 🎧 Listen to the full episode of Conversations in Lung Cancer Research now. Listen on Apple > buff.ly/due1sdz

Interested in developing your expertise in thoracic oncology? TOGA’s 2026 Lung Cancer Preceptorship provides early-career clinicians with the opportunity to learn from experienced clinicians, engage in practical case-based discussions and build connections with others working in the field.

Great discoveries start with great ideas. TOGA's Inspirational Research Grant supports research that addresses important questions in thoracic oncology, with the potential to influence future clinical practice and improve outcomes for patients. Grant details: 💰 Amount: $50,000

We're pleased to welcome Pfizer as a sponsor of TOGA's 2026 Lung Cancer Preceptorship. Thank you for supporting this important educational initiative and helping create opportunities for the next generation of thoracic oncology clinicians to learn, connect and grow. 📅 Dates: November 20-21

🎙️ New episode available A/Prof Mel Moore welcomes Prof Zarnie Lwin OAM for a wide-ranging conversation about her journey in lung cancer research and clinical care. Listen on Apple > buff.ly/due1sdz Spotify > buff.ly/Zde8VHx Show Notes > buff.ly/Qc1N28c